|
|
Support : Dialog Search Aids
: Pharmaprojects Therapeutic Class Codes
Pharmaprojects Therapeutic Class Codes
(DIALOG Files 128*, 928*)
*(Subscriber access.)
 View the PDF version of this document
This list includes the therapeutic categories
in order of their codes. This allows you to
see the hierarchy involved in the classification.
| N |
NEUROLOGICAL PRODUCTS |
| N1A1 |
ANAESTHETIC, INHALATION
General anaesthetics administered by inhalation and act on the brain to produce loss of consciousness. |
| N1A2 |
ANAESTHETIC, INJECTABLE
General anaesthetics administered by parenteral routes which produce a rapid induction of anaesthesia. Products include barbiturates and opioids eg m opioid agonists. |
| N1B |
ANAESTHETIC, LOCAL
Local anaesthetics act by blocking conduction in nerve trunks and thus decrease the sensation of pain. These compounds belong to the class of membrane stabilising drugs. |
| N2B |
ANALGESIC, NSAID
Analgesics that are classified as non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs inhibit the formation of prostaglandins from arachidonic acid via the cyclo-oxygenase pathway. Products in development include salicylates eg ASA thioesters, indometacin-like drugs and propionic acid derivatives eg ibuprofen. |
| N2Z |
ANALGESIC, OTHER
Analgesic drugs that are not classified as non-steroidal anti-inflammatory drugs (NSAIDs). The majority of the products included in this section act on pain perception within the central nervous system. Compounds under investigation include opioids eg partial and mixed agonist/antagonist m opioids and short-acting m agonists, enkephalins, enkephalinase inhibitors, antagonists of endogenous kallikreins, kinins, 5-HT and substance P, and paracetamol formulations. |
| N3A |
ANTIEPILEPTIC
Epilepsies are a group of central nervous system (CNS) disorders having in common the repeated occurrence of sudden and transitory episodes (seizures) of abnormal phenomena of motor (convulsion), sensory, autonomic, or psychic origin. Products in development include hydantoins, barbiturates, iminostilbines, benzodiazepines and excitatory amino acids (EAA) antagonists eg NMDA antagonists. |
| N4A |
ANTIPARKINSONIAN
Drugs that are effective in Parkinson's disease and in the dyskinesias, hyperkinesias (Sydenham's chorea and Huntingdon's chorea), athetosis, ballism, Wilson's disease, hypertonicity (hemiplegia, monoplegia, tetanus and stiff-man syndrome) and cerebellar diseases (dysmetria, dysdiadochokinesia and ataxia). Products in development include formulations of dopamine and dopamine potentiating agents, and MAO inhibitors. |
| N5A1 |
NEUROLEPTIC
Neuroleptic (antipsychotic, or major tranquillisers) agents are used in the treatment of psychoses such as schizophrenia, paranoia, and delirium. Drugs under investigation include dopamine autoreceptor agonists, 5-HT3 antagonists, 5-HT1A antagonists and 5-HT reuptake inhibitors, triazolobenzodiazepines and selective sigma opioid ligands. |
| N5B |
HYPNOTIC/SEDATIVE
Hypnotics are drugs used to produce drowsiness and sleep, whereas sedatives are used to calm anxious and restless patients, thus allowing sleep without actually producing it. Drugs under development include benzodiazepines, barbiturates, 5-HT2 antagonists and non-indolic melatonin (ML-1) receptor agonists. |
| N5C |
ANXIOLYTIC
Drugs that are used to treat anxiety and panic attacks including benzodiazepines, benzodiazepine-like products eg b -carboline derivatives, selective monocyclic 5-HT reuptake inhibitors, 5-HT2 and 5-HT3 antagonists, selective omega1-agonists and MAO-A inhibitors. |
| N5D |
ANTINEUROTIC
Drugs that are being developed for the treatment of neuroses, including phobias, obsessive-compulsive disorders and eating neuroses such as anorexia nervosa and bulimia. Compounds under investigation include selective monocyclic 5-HT reuptake inhibitors, 5-HT1A agonists and MAO-A inhibitors. |
| N6B |
PSYCHOSTIMULANT
Products that increase psychomotor activity for the treatment of narcolepsy, cataplexy, sleep paralysis and attention-deficit hyperactivity disorders. Agents under development include a 1-agonists, 5-HT antagonists, competitive melatonin antagonists and thyrotrophin releasing hormone (protirelin) analogues. |
| N6D |
COGNITION ENHANCER
Products that are used in the treatment of a variety of dementias including Alzheimer's disease. These cognition enhancers are sometimes called nootropic agents. Approaches under investigation include antagonists that act at a unique -amyloid peptide receptor site on neuroglia, neural stem cells, nerve growth factors, acetylcholinesterase inhibitors and NMDA antagonists |
| N7A |
MULTIPLE SCLEROSIS TREATMENT
Multiple sclerosis is a demyelinating disease in which nerves are stripped of their myelin "covering". Products under investigation include humanised anti-Tac antibodies, recombinant human b -interferon, immunosuppressant agents, myelin basic protein (MBP) and proteolipid protein (PLP) and glial growth factors. |
| N7C |
NEUROPROTECTIVE
Products that are used for the treatment of cerebrovascular disease, including cerebral ischaemia, anoxia, cerebral/subarachnoid haemorrhage and stroke. Treatments for amyotrophic lateral sclerosis (Lou Gehrig's disease). Compounds under investigation include calcium antagonists, 5-HT2 antagonists, NMDA receptor antagonists, calpain inhibitors, protein kinase inhibitors, adenosine agonists and growth factors. |
| N8A |
ANTIMIGRAINE
Drug treatment of migraine has two main aims, to relieve symptoms of an attack, and prophylactically to reduce the frequency and intensity of the attacks. Products include selective 5-HT1-like agonists, 5-HT2 antagonists, calcium antagonists, semisynthetic ergot alkaloids, nitric oxide (NO) synthetase inhibitors and bradykinin antagonists. |
| N9A |
DEPENDENCE TREATMENT
Products to reduce the craving including selective m opioid receptor antagonists and d opioid agonists, 5-HT3 antagonists, non-addictive non-nicotine compounds and transdermal nicotine patches. |
| N10A |
ANTIDEPRESSANT
Depression is associated with imbalances between various neurotransmitters produced in the brain, such as norepinephrine, dopamine and 5-HT. Products in development include tricyclic antidepressants, MAO-A and MAO-B inhibitors, selective 5-HT reuptake inhibitors, norepinephrine uptake inhibitors, selective 5-HT2, 5-HT3 and 5-HT1D antagonists, a 2-antagonists and competitive melatonin receptor antagonists. |
| N11Z |
NEUROLOGICAL
Neurological compounds which are being developed for unspecific CNS indications or cannot be classified in any of the "N" categories. Drugs that are used in the treatment of diabetic neuropathy eg ciliary neurotrophin factor analogues. Products in development include various nerve growth factors, proteolytic enzyme inhibitors, NMDA antagonists and tyrosine kinase inhibitors. |
Last modified on 24 Feb 2012.
top
|
Related Search Aid:
Pharmaprojects (DIALOG Files 128, 928) Major Events in the Update Information (UP) Field
|
Dialog1
Support Home